Search results
Results from the WOW.Com Content Network
There are targeted therapies for lung cancer, colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, lymphoma, prostate cancer, melanoma and other cancers. [ 1 ] [ 3 ] [ 4 ] Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy.
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
The therapy can effectively decrease symptoms by reducing the size of the tumor, or by decreasing the tumor's impact, for example by decreasing the tumor's production of hormones. [ 7 ] Primary liver tumors, metastatic neuroendocrine tumors to the liver [ 8 ] and other metastases to the liver [ 9 ] [ 10 ] may be considered for therapy directed ...
In a study published in the journal Melanoma Research, the team found liver cancers were controlled in 88.9% of patients who had received chemosaturation therapy, with 62% of them surviving for a ...
Radiation therapy is used to kill cancer cells; however, normal cells are also damaged in the process. Currently, therapeutic doses of radiation can be targeted to tumors with great accuracy using linear accelerators in radiation oncology; however, when irradiating using external beam radiotherapy, the beam will always need to travel through healthy tissue, and the normal liver tissue is very ...
1990s – RFA for soft tissue tumors, i.e., bone, breast, kidney, lung and liver cancer. 1997 – Intra-arterial delivery of tumor-killing viruses and gene therapy vectors to the liver. 1997 – HIFU first used to treat prostate cancer. 2012 – Pioneering liver chemoperfusion study reported by Delcath for disseminated liver metastases. [32]
As a result, the entire antibody, linker and cytotoxic (anti-cancer) agent enter the targeted cancer cell where the antibody is degraded into an amino acid. The resulting complex – amino acid, linker and cytotoxic agent – is considered to be the active drug. In contrast, cleavable linkers are detached by enzymes in the cancer cell. The ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!